Biology Reference
In-Depth Information
6. Bonvini P, Zorzi E, Mussolin L, Monaco G, Pigazzi M, Basso G,
Rosolen A. (2009) The effect of the cyclin-dependent kinase
inhibitor flavopiridol on anaplastic large cell lymphoma cells and
relationship with NPM-ALK kinase expression and activity.
Haematologica
2009;94:944
27. Ling MM, Robinson BH. Approaches to DNA mutagenesis: an
overview.
Anal Biochem
1997;254:157
78.
28. Joyce CM, Steitz TA. Function and structure relationships in
DNA polymerases.
Annu Rev Biochem
1994;63:777
e
e
822.
29. Goodman MF. Error-prone
repair DNA polymerases
in
55.
7. Fitzpatrick FA, Wheeler R. The immunopharmacology of pacli-
taxel (Taxol), docetaxel (Taxotere), and related agents.
Int Immu-
nopharmacol
2003;3:1699
e
50.
30. Shcherbakova PV, Bebenek K, Kunkel TA. Functions of eukary-
otic DNA polymerases.
Sci Aging Knowledge Environ
2003;8. RE3.
31. Hubscher U, Maga G, Spadari S. Eukaryotic DNA polymerases.
Annu Rev Biochem
2002;71:133
prokaryotes and eukaryotes.
Annu Rev Biochem
2002;71:17
e
714.
8. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer
cells?
J Cell Sci
2009;122:2579
e
63.
32. Sutton MD. Coordinating DNA polymerase traffic during high
and low fidelity synthesis.
Biochim Biophys Acta
2010;1804:
1167
e
85.
9. Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca
alkaloids.
Cancer Surv
1993;17:269
e
81.
10. Tolentino JH, Burke TJ, Mukhopadhyay S, McGregor WG,
Basu AK. Inhibition of DNA replication fork progression and
mutagenic potential of 1, N6-ethenoadenine and 8-oxoguanine in
human cell extracts.
Nucleic Acids Res
2008;36:1300
e
79.
33. Joyce CM, Benkovic SJ. DNA polymerase fidelity: kinetics,
structure, and checkpoints.
Biochemistry
2004;43:14317
e
24.
34. Kunkel TA, Bebenek K. DNA replication fidelity.
Annu Rev Bio-
chem
2000;69:497
e
8.
11. Essigmann JM, Rink SM, Park HJ, Croy RG. Design of DNA
damaging agents that hijack transcription factors and block DNA
repair.
Adv Exp Med Biol
2001;500:301
e
529.
35. Kuchta RD, Stengel G. Mechanism and evolution of DNA pri-
mases.
Biochim Biophys Acta
2010;1804:1180
e
9.
36. Downey KM, Tan CK, So AG. DNA polymerase delta: a second
eukaryotic DNA replicase.
Bioessays
1990;12:231
e
13.
12. Kluza J, Mazinghien R, Irwin H, Hartley JA, Bailly C. (2006)
Relationships between DNA strand breakage and apoptotic
progression upon treatment of HL-60 leukemia cells with taflu-
poside or etoposide.
Anticancer Drugs
2006;17:155
e
6.
37. Pursell ZF, Kunkel TA. DNA polymerase epsilon: a polymerase of
unusual size (and complexity).
Prog Nucleic Acid Res Mol Biol
2008;82:101
e
64.
13. Bridgewater LC, Manning FC, Patierno SR. Arrest of replication
by mammalian DNA polymerases alpha and beta caused by
chromium-DNA lesions.
Mol Carcinog
1998;23:201
e
45.
38. Kunkel TA, Burgers PM. Dividing the workload at a eukaryotic
replication fork.
Trends Cell Biol
2008;18:521
e
7.
39. Prescott JC, Blackburn EH. Telomerase: Dr Jekyll or Mr Hyde?
Curr Opin Genet Dev
1999;9:368
e
6.
14. Randerath K, Randerath E, Zhou GD, Li D. Bulky endogenous
DNA modifications (I-compounds) - possible structural origins
and functional implications.
Mutat Res
1999;424:183
e
73.
40. Cheung AL, Deng W. Telomere dysfunction, genome instability
and cancer.
Front Biosci
2008;13:2075
e
94.
15. Cruet-Hennequart S, Gallagher K, Sok
`
l AM, Villalan S,
Prendergast AM, Carty MP. DNA polymerase eta, a key protein
in translesion synthesis
e
90.
41. Kelland L. Targeting the limitless replicative potential of cancer:
the telomerase/telomere pathway.
Clin Cancer Res
2007;13:4960
e
3.
42. Bailey CM, Anderson KS. A mechanistic view of human mito-
chondrial DNA polymerase gamma: providing insight into drug
toxicity and mitochondrial disease.
Biochim Biophys Acta
2010;
1804:1213
e
in human cells.
Subcell Biochem
209.
16. Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics
of anti-metabolites.
Cancer Surv
1993;17:123
2010;50:189
e
56.
17. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR,
Bergman AM, Ackland SP. (2000) Basis for effective combination
cancer chemotherapy with antimetabolites.
Pharmacol Ther
2000;
87:227
e
22.
43. BeardWA,WilsonSH. Structural designof a eukaryoticDNArepair
polymerase: DNA polymerase beta.
Mutat Res
2000;460:231
e
44.
44. Lieber MR, Gu J, Lu H, Shimazaki N, Tsai AG. Nonhomologous
DNA end joining (NHEJ) and chromosomal translocations in
humans.
Subcell Biochem
2010;50:279
e
53.
18. Garc´a F, Fumero E, Gatell JM. Immune modulators and treat-
ment interruption.
Curr Opin HIVAIDS
2008;3:124
e
96.
45. Gucalp R, Paietta E, Weinberg V, Papenhausen P, Dutcher JP,
Wiernik PH. Terminal transferase expression in acute myeloid
leukaemia: biology and prognosis.
Br J Haematol
1991;78:48
e
30.
19. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by
9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for
cytotoxicity.
J Biol Chem
1990;265:16617
e
54.
46. Marshall AJ, Doyen N, Bentolila LA, Paige CJ, Wu GE. Terminal
deoxynucleotidyl transferase expression during neonatal life
alters D(H) reading frame usage and Ig-receptor-dependent
selection of V regions.
J Immunol
1998;161:6657
e
25.
20. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks
gemcitabine-induced stalled replication forks and their collapse
upon S-phase checkpoint abrogation.
Mol Cancer Ther
2007;6:
1239
e
63.
47. Long JC, McCaffrey RP, Aisenberg AC, Marks SM, Kung PC.
Terminal deoxynucleotidyl transferase positive lymphoblastic
lymphoma: a study of 15 cases.
Cancer
1979;44:2127
e
48.
21. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors
and future drug design.
Curr Cancer Drug Targets
2006;6:409
e
31.
22. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine:
a modulator of intracellular nucleotide and deoxynucleotide
metabolism.
Semin Oncol
1995;22:11
e
39.
48. Kung PC, Long JC, McCaffrey RP, Ratliff RL, Harrison TA,
Baltimore D. Terminal deoxynucleotidyl transferase in the diag-
nosis of leukemia and malignant lymphoma.
Am J Med
1978;
64:788
e
8.
23. van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van
Haperen VW, Kroep JR, Pinedo HM, Peters GJ. Differential effects
of gemcitabine on ribonucleotide pools of
e
94.
49. Del Poeta G, Venditti A, Stasi R, et al. P-glycoprotein and terminal
transferase expression identify prognostic subsets within cyto-
genetic risk classes in acute myeloid leukemia.
Leuk Res
1999;23:451
e
twenty-one solid
tumour and leukaemia cell
lines.
Biochim Biophys Acta
2000;
12.
24. White L, Siegel SE, Quah TC. Non-Hodgkin's lymphomas in
children. II. Treatment.
Crit Rev Oncol Hematol
1992;13:73
1474:5
e
65.
50. Burgers PM. Eukaryotic DNA polymerases alpha and delta:
conserved properties and interactions, from yeast to mammalian
cells.
Prog Nucleic Acid Res Mol Biol
1989;37:235
e
89.
25. Robak T. Recent progress in the management of chronic
lymphocytic leukemia.
Cancer Treat Rev
2007;33:710
e
80.
51. Yuan F, Zhang Y, Rajpal DK, et al. Specificity of DNA lesion
bypass by the yeast DNA polymerase eta.
J Biol Chem
2000;
275:8233
e
28.
26. Aranha O, Benson 3rd AB. Adjuvant therapy for colon cancer.
Curr Gastroenterol Rep
2007;9:415
e
e
21.
e
9.
